Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to...
www.jdsupra.com
October 22, 2026 at 6:15 PM
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to...
www.jdsupra.com
October 22, 2026 at 6:15 PM
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to...
www.jdsupra.com
October 22, 2026 at 6:15 PM
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Can anyone clarify what is happening in the UK to thyroid hormone products (levothyroxine and liothyronine) from Advanz Pharma / Mercury Pharma - including Eltroxin?
#thryoid
#hypothyroidism
#levothyroxine
#liothyronine
#advanz
#mercurypharma
#eltroxin
#thryoid
#hypothyroidism
#levothyroxine
#liothyronine
#advanz
#mercurypharma
#eltroxin
October 14, 2026 at 12:18 PM
Can anyone clarify what is happening in the UK to thyroid hormone products (levothyroxine and liothyronine) from Advanz Pharma / Mercury Pharma - including Eltroxin?
#thryoid
#hypothyroidism
#levothyroxine
#liothyronine
#advanz
#mercurypharma
#eltroxin
#thryoid
#hypothyroidism
#levothyroxine
#liothyronine
#advanz
#mercurypharma
#eltroxin
Have they discontinued some or all thyroid hormone products? Tablets and liquids and injectable?
Are they rebranding as Advanz and not Mercury? Or totally pulling out?
Is it legal for them to ignore all attempts to communicate by phone or email?
Are they rebranding as Advanz and not Mercury? Or totally pulling out?
Is it legal for them to ignore all attempts to communicate by phone or email?
October 14, 2026 at 12:18 PM
Have they discontinued some or all thyroid hormone products? Tablets and liquids and injectable?
Are they rebranding as Advanz and not Mercury? Or totally pulling out?
Is it legal for them to ignore all attempts to communicate by phone or email?
Are they rebranding as Advanz and not Mercury? Or totally pulling out?
Is it legal for them to ignore all attempts to communicate by phone or email?
#ALVO Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Alvotech (ALVO) and Advanz Pharma announced a European regulatory submission for AVT29, a proposed biosimilar to Eylea 8 mg. The application was submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli, Alvotech’s biosimilar to Eylea 2 mg. Mynzepli received European Commission approval in August 2025 in vial and prefilled syringe presentations for various retinal diseases.Alvotech is responsible for development and commercial supply of AVT06 and AVT29, while Advanz Pharma handles registration and commercialization in Europe. The approved European information for Eylea 8 mg allows 16-week treatment intervals for certain patients, compared with the standard eight-week maintenance interval for the original 2 mg formulation. AVT29 remains investigational; regulatory authorities have not yet established its biosimilarity.
www.stocktitan.net
October 14, 2026 at 8:30 AM
#ALVO Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social
$PYPD — Foreign Issuer Report
PolyPid Ltd. (Nasdaq: PYPD) announced the mutual termination of its 2022 exclusive License, Distribution and Supply Agreement with ADVANZ PHARMA (Mercury Pharma Group Limited) for D-PLEX100 in Europe, thereby regaining exclusive European commercializa...
🧵 continued ↓
PolyPid Ltd. (Nasdaq: PYPD) announced the mutual termination of its 2022 exclusive License, Distribution and Supply Agreement with ADVANZ PHARMA (Mercury Pharma Group Limited) for D-PLEX100 in Europe, thereby regaining exclusive European commercializa...
🧵 continued ↓
October 1, 2026 at 4:31 PM
$PYPD — Foreign Issuer Report
PolyPid Ltd. (Nasdaq: PYPD) announced the mutual termination of its 2022 exclusive License, Distribution and Supply Agreement with ADVANZ PHARMA (Mercury Pharma Group Limited) for D-PLEX100 in Europe, thereby regaining exclusive European commercializa...
🧵 continued ↓
PolyPid Ltd. (Nasdaq: PYPD) announced the mutual termination of its 2022 exclusive License, Distribution and Supply Agreement with ADVANZ PHARMA (Mercury Pharma Group Limited) for D-PLEX100 in Europe, thereby regaining exclusive European commercializa...
🧵 continued ↓
#PYPD PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
https://www.stocktitan.net/news/PYPD/poly-pid-regains-european-commercialization-rights-for-d-plex100-r9ui7f9af7hf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PYPD/poly-pid-regains-european-commercialization-rights-for-d-plex100-r9ui7f9af7hf.html?utm_source=stocktitan-bluesky&utm_medium=social
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
PolyPid (PYPD) has regained exclusive European commercialization rights for D-PLEX₁₀₀ following the mutually agreed termination of its agreement with ADVANZ PHARMA.The terminated 2022 agreement covered licensing, distribution and supply in Europe. PolyPid has completed its Phase 3 SHIELD II trial, its New Drug Application submission to the US Food and Drug Administration and its EMA submission. D-PLEX₁₀₀ met the trial’s primary and all key secondary endpoints for preventing surgical site infections. PolyPid also established a North American commercialization partnership with Azurity Pharmaceuticals. The company believes these milestones make D-PLEX₁₀₀ attractive to multinational pharmaceutical companies for Europe and other large markets.
www.stocktitan.net
October 1, 2026 at 12:56 PM
#PYPD PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
https://www.stocktitan.net/news/PYPD/poly-pid-regains-european-commercialization-rights-for-d-plex100-r9ui7f9af7hf.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PYPD/poly-pid-regains-european-commercialization-rights-for-d-plex100-r9ui7f9af7hf.html?utm_source=stocktitan-bluesky&utm_medium=social
Unintentionally!
Debranded. Raised prices. Extracted money.
Then got fined.
Though I do not know the overall debt/money extraction picture.
www.gov.uk/government/n...
Debranded. Raised prices. Extracted money.
Then got fined.
Though I do not know the overall debt/money extraction picture.
www.gov.uk/government/n...
Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices
The Court of Appeal has unanimously upheld the CMA’s finding that Advanz broke the law by overcharging the NHS for essential thyroid drug liothyronine.
www.gov.uk
August 13, 2026 at 8:40 AM
Unintentionally!
Debranded. Raised prices. Extracted money.
Then got fined.
Though I do not know the overall debt/money extraction picture.
www.gov.uk/government/n...
Debranded. Raised prices. Extracted money.
Then got fined.
Though I do not know the overall debt/money extraction picture.
www.gov.uk/government/n...
Alvotech与Advanz Pharma达成欧洲生物仿制药商业化合作，开拓慢性风湿病市场新机遇
https://qian.cx/posts/DA60A470-5826-45C0-B26D-ED91144EFC94
https://qian.cx/posts/DA60A470-5826-45C0-B26D-ED91144EFC94
October 12, 2025 at 5:14 AM
Alvotech与Advanz Pharma达成欧洲生物仿制药商业化合作，开拓慢性风湿病市场新机遇
https://qian.cx/posts/DA60A470-5826-45C0-B26D-ED91144EFC94
https://qian.cx/posts/DA60A470-5826-45C0-B26D-ED91144EFC94
Generic kesimpta is coming to Europe. Alvotech intends to develop a biosimilar formulation. multiplesclerosisnewstoday.com/news-posts/2...
Partners to commercialize Kesimpta biosimilar MS drug in Europe
Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta biosimilar drug for MS.
multiplesclerosisnewstoday.com
June 3, 2025 at 8:18 PM
Generic kesimpta is coming to Europe. Alvotech intends to develop a biosimilar formulation. multiplesclerosisnewstoday.com/news-posts/2...
…finding Advanz gouged the NHS over drug pricing. If Rajagopalan were to be disqualified, it would force Cinven to change its leadership for a second time in two years, calling into question the firm’s image as a steady and reliable private equity manager. @alexandraheal.bsky.social
November 21, 2025 at 11:26 PM
…finding Advanz gouged the NHS over drug pricing. If Rajagopalan were to be disqualified, it would force Cinven to change its leadership for a second time in two years, calling into question the firm’s image as a steady and reliable private equity manager. @alexandraheal.bsky.social
Big pharma picking our pockets.
Advanz, the sole supplier of liothyronine tablets (thyroid drug) in the UK, hiked price from £20 to £248 per box – an increase of over 1,110%.
Corporations devour everything, have no ethics.
Must return to Labour's 2019 manifesto - govt to produce generic drugs.
Advanz, the sole supplier of liothyronine tablets (thyroid drug) in the UK, hiked price from £20 to £248 per box – an increase of over 1,110%.
Corporations devour everything, have no ethics.
Must return to Labour's 2019 manifesto - govt to produce generic drugs.
Court upholds CMA’s £99m fine on pharma over excessive NHS thyroid drug prices
The Court of Appeal has unanimously upheld the CMA’s finding that Advanz broke the law by overcharging the NHS for essential thyroid drug liothyronine.
www.gov.uk
August 22, 2025 at 3:24 PM
Big pharma picking our pockets.
Advanz, the sole supplier of liothyronine tablets (thyroid drug) in the UK, hiked price from £20 to £248 per box – an increase of over 1,110%.
Corporations devour everything, have no ethics.
Must return to Labour's 2019 manifesto - govt to produce generic drugs.
Advanz, the sole supplier of liothyronine tablets (thyroid drug) in the UK, hiked price from £20 to £248 per box – an increase of over 1,110%.
Corporations devour everything, have no ethics.
Must return to Labour's 2019 manifesto - govt to produce generic drugs.
Alvotech и Advanz Pharma объявляют о стратегическом соглашении по коммерциализации биосимиляров в Европе
https://kripta.biz/posts/414CF171-DAC4-4A79-B19F-4085B5137DD2
https://kripta.biz/posts/414CF171-DAC4-4A79-B19F-4085B5137DD2
October 12, 2025 at 5:14 AM
Alvotech и Advanz Pharma объявляют о стратегическом соглашении по коммерциализации биосимиляров в Европе
https://kripta.biz/posts/414CF171-DAC4-4A79-B19F-4085B5137DD2
https://kripta.biz/posts/414CF171-DAC4-4A79-B19F-4085B5137DD2
📣 ¡Advanz Informática renueva con el club!
💻 Venta y reparación de ordenadores, móviles y consolas
🌐 Desarrollo web y soporte técnico
📍 C/ Cardenal Spínola, 1
📲 @advanzinformatica
🙏 ¡Gracias por seguir confiando en nosotros!
💻 Venta y reparación de ordenadores, móviles y consolas
🌐 Desarrollo web y soporte técnico
📍 C/ Cardenal Spínola, 1
📲 @advanzinformatica
🙏 ¡Gracias por seguir confiando en nosotros!
August 7, 2025 at 11:02 AM
📣 ¡Advanz Informática renueva con el club!
💻 Venta y reparación de ordenadores, móviles y consolas
🌐 Desarrollo web y soporte técnico
📍 C/ Cardenal Spínola, 1
📲 @advanzinformatica
🙏 ¡Gracias por seguir confiando en nosotros!
💻 Venta y reparación de ordenadores, móviles y consolas
🌐 Desarrollo web y soporte técnico
📍 C/ Cardenal Spínola, 1
📲 @advanzinformatica
🙏 ¡Gracias por seguir confiando en nosotros!
guy who named bartz advanz
May 20, 2025 at 2:35 AM
guy who named bartz advanz
EC approves Gobivaz, the first biosimilar to Simponi (golimumab) in the EEA. Developed by Alvotech and commercialised by Advanz Pharma, it’s approved for multiple immune-mediated diseases in adults and children.
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
Gobivaz approved across Europe as first Simponi biosimilar - PharmaTimes
Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases
pharmatimes.com
December 30, 2025 at 10:15 PM
EC approves Gobivaz, the first biosimilar to Simponi (golimumab) in the EEA. Developed by Alvotech and commercialised by Advanz Pharma, it’s approved for multiple immune-mediated diseases in adults and children.
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial www.nature.com/articles/s41... #hvhebron #medint [Text complet] @nature.com
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial - Nature Communications
Advanced HIV-1 infection is associated with gut dysbiosis, and it’s not known whether this is reversed with antiviral therapy. The ADVANZ-4 MISTRAL trial shows that dolutegravir restores gut microbiot...
www.nature.com
March 18, 2026 at 10:41 AM
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial www.nature.com/articles/s41... #hvhebron #medint [Text complet] @nature.com
Immune reconstitution in very advanced HIV patients treated with Dolutegravir vs Darunavir-based triple antiretroviral therapy. The Advanz-4 randomized clinical trial www.sciencedirect.com/science/arti... #hvhebron #medint
Immune reconstitution in very advanced HIV patients treated with Dolutegravir vs Darunavir-based triple antiretroviral therapy. The Advanz-4 randomized clinical trial
The aim of this trial was to compare the immune reconstitution, virologic response, and safety of dolutegravir (DTG)- vs. darunavir (DRV) boosted-base…
www.sciencedirect.com
October 15, 2025 at 11:11 AM
Immune reconstitution in very advanced HIV patients treated with Dolutegravir vs Darunavir-based triple antiretroviral therapy. The Advanz-4 randomized clinical trial www.sciencedirect.com/science/arti... #hvhebron #medint
European Biosimilar Updates - Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
European Biosimilar Updates - Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
On August 21, 2025, Alvotech and Advanz Pharma Holdco Limited (“Advanz”) announced that MYNZEPLI®, a biosimilar of Regeneron’s EYLEA®...
www.jdsupra.com
September 3, 2025 at 5:34 PM
European Biosimilar Updates - Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
European Biosimilar Updates - Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
European Biosimilar Updates - Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
On August 21, 2025, Alvotech and Advanz Pharma Holdco Limited (“Advanz”) announced that MYNZEPLI®, a biosimilar of Regeneron’s EYLEA®...
www.jdsupra.com
September 3, 2025 at 5:34 PM
European Biosimilar Updates - Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance
Advanz Pharma has confirmed that hydrocortisone sodium phosphate has been permanently discontinued in the UK.
💉If you have adrenal insufficiency, including Addison’s, you'll need to order the alternative, hydrocortisone sodium succinate, for emergency injection kits.
➡️ https://loom.ly/1l2GmG0
💉If you have adrenal insufficiency, including Addison’s, you'll need to order the alternative, hydrocortisone sodium succinate, for emergency injection kits.
➡️ https://loom.ly/1l2GmG0
March 25, 2026 at 5:14 PM
Advanz Pharma has confirmed that hydrocortisone sodium phosphate has been permanently discontinued in the UK.
💉If you have adrenal insufficiency, including Addison’s, you'll need to order the alternative, hydrocortisone sodium succinate, for emergency injection kits.
➡️ https://loom.ly/1l2GmG0
💉If you have adrenal insufficiency, including Addison’s, you'll need to order the alternative, hydrocortisone sodium succinate, for emergency injection kits.
➡️ https://loom.ly/1l2GmG0
Aifa segnala ritiro lotti medicinale per trattamento patologia del fegato. Ecco info
www.reportsardegna24.it/aifa-segnala...
www.reportsardegna24.it/aifa-segnala...
Aifa segnala ritiro lotti medicinale per trattamento patologia del fegato. Ecco info | Report Sardegna 24
L’Aifa, a tutela della salute pubblica, con provvedimento del 24.12.2024, ha disposto il ritiro di tutti i lotti del medicinale “OCALIVA” AIC n. 045222/E della ditta Advanz Pharma Specialty Medicine I...
www.reportsardegna24.it
December 29, 2024 at 11:01 AM
Aifa segnala ritiro lotti medicinale per trattamento patologia del fegato. Ecco info
www.reportsardegna24.it/aifa-segnala...
www.reportsardegna24.it/aifa-segnala...